• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

Medical News Interviews

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Audio Journal of Oncology in Advance – October 1st, 2006

0
  • by alexperjescuadmin
  • in AJO · Oncology
  • — 1 Oct, 2006
Audio Journal of Oncology in Advance - October 1st, 2006
AudioMedica News
Audio Journal of Oncology in Advance - October 1st, 2006
Audio Journal of Oncology in Advance - October 1st, 2006
00:00 /
RSS Feed
Share
Link
Embed
//-->//>' class="input-embed input-embed-202"/>
George Canellos
George Canellos
Sandra Strauss
Sandra Strauss
Nancy Baxter
Nancy Baxter

KIT Mutations in Acute Myeloid Leukemia Confer Higher Relapse Risk
Liver Metastasis Resection Not Curative for Colorectal Cancer
Patients With Node Negative Breast Cancer: Low Risk After Mastectomy

REFERENCES: J Clin Oncol 34:3904, 3927, 3939
GEORGE CANELLOS, Dana-Farber Cancer Institute, Boston
In adult acute myeloid leukemia the detection of KIT mutations was associated with higher relapse risk, according to a study from Columbus, Ohio, reviewed by George Canellos. Dr Canellos also discussed findings from Paris that complete dissection of liver metastasis is not curative for colorectal cancer, and results from Boston that patients with large breast cancers removed by mastectomy may expect low locoregional recurrence rates if they are lymph-node negative, and therefore do not need postmastectomy radiotherapy.

Combination Immunotherapy: Promising For Patients With Refractory or Recurrent Non-Hodgkin’s Lymphoma

REFERENCE: J Clin Oncol 24:3880
SANDRA STRAUSS, Royal Free Hospital, London
COMMENT: George Canellos

A new combination of immunotherapy agents – the anti-CD22 antibody epratuzumab and the anti CD20 rituximab – has shown promise for the treatment of patients whose non-Hodgkin’s lymphoma is recurrent or has become refractory to standard therapy. Sandra Strauss of London’s Royal Free Hospital told Peter Goodwin about the findings from her study published in the Journal of Clinical Oncology.

Stage IIIB, IIIC Colon Cancer: Negative Lymph Nodes, Longer Survival

REFERENCE: J Clin Oncol 24:3570
NANCY BAXTER, St Michael’s Hospital, Toronto
COMMENT: George Canellos

In Stage III colon cancer having fewer negative lymph nodes leads to shorter survival, according to the findings of a study from St Michael’s Hospital in Toronto. Having more negative nodes is associated with longer survival. Nancy Baxter discussed the investigation with Derek Thorne.


[audio:https://www.audiomedica.com/podcasting/asco/061001_asco_podcast.mp3]
Share

Tags: breastcoloncolorectalimmunotherapyKITleukemialiverlymphomamastectomymetastatis

You may also like...

  • Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes 10 Dec, 2007
  • Trifluridine with Tipiracil Lifts Survival in Refractory Gastric Cancer Trifluridine with Tipiracil Lifts Survival in Refractory Gastric Cancer 11 Oct, 2018
  • Bivalent Vaccine for HPV: Interim Phases III Data Show High Efficacy Bivalent Vaccine for HPV: Interim Phases III Data Show High Efficacy 2 Aug, 2007
  • BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib 1 Nov, 2018

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Reporting from the 2006 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, San Francisco
  • Next story Audio Journal of Medicine: Reporting from the 2006 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, San Francisco
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • Breast Cancer: Combined Risk Assessment Prompts…
    • Microbiome Diversity Key To Survival After…
    • Brachytherapy “Excellent” After Breast…
  • Home
  • Oncology
  • AJO
  • Audio Journal of Oncology in Advance – October 1st, 2006

© Copyright 2021 AudioMedica.com. Typegrid Theme by WPBandit.